PDF herunterladen
Laryngorhinootologie 2016; 95(12): 828-830
DOI: 10.1055/s-0042-118096
Übersicht
© Georg Thieme Verlag KG Stuttgart · New York

Gastroösophageale Refluxerkrankung und maligne Transformation – für Männer und Frauen ein gleich großes Risiko?

Gastro-Esophageal Reflux Disease and Malignant Progression – Equal Risk for Men and Women?
O. Pech
1   Department for Gastroenterology and Interventional Endoscopy, Krankenhaus Barmherzige Brüder, Regensburg
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
04. Januar 2018 (online)

Auch verfügbar auf
    Lizenzen und Reprints

Zusammenfassung

Die gastroösophageale Refluxerkrankung (GERD) hat gerade in der westlichen Welt eine hohe Prävalenz. Patienten mit GERD haben ein etwa 10%-iges Risiko einen Barrett-Ösophagus zu entwickeln, der wiederum ein Risiko für die Entstehung eines ösophagealen Adenokarzinoms darstellt. Männer haben eine höhere Intensität der GERD in Hinblick auf den Grad der Entzündung und den Säurereflux. Aus diesem Grund ist das Risiko einen Barrett-Ösophagus zu entwickeln bei Männern etwa 2–3-fach erhöht und für ein ösophageales Adenokarzinom sogar 3–6-mal höher als bei Frauen.

Abstract

Gastroesophageal reflux disease (GERD) is highly prevalent in the Western world. Patients with GERD have a 10-fold increased risk to develop a Barrett’s esophagus. Patients with Barrett’s esophagus have a higher risk for an esophageal adenocarcinoma. Men have more severe reflux with a higher grade of inflammation and acid reflux. This seems to be the reason why men develop a Barrett’s esophagus more frequently – the risk is approximately 2–3-fold and the risk for an esophageal adenocarcinoma is even 3–6 times higher.

Schlüsselwörter

Barrett-Ösophagus - Ösophaguskarzinom - Refluxösophagititis - GERD

Key words

Barrett’s esophagus - esophageal cancer - reflux esophagititis - GERD
 

  • Literatur

  • 1 El-Serag HB, Sweet S, Winchester CC, Dent J. Update on the epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut 2014; 63: 871-880
    CrossrefPubMedGoogle Scholar
  • 2 Gerson L, Shetler K, Triadafilopoulos G. Prevalence of Barrett’s esophagus in asymptomatic individuals. Gastroenterology 2002; 123: 461-467
    CrossrefPubMedGoogle Scholar
  • 3 Rex DK, Cummings OW, Shaw M, Cumings MD, Wong RK, Vasudeva RS, Dunne D, Rahmani EY, Helper DJ. Screening for Barrett’s esophagus in colonoscopy patients with and without heartburn. Gastroenterology 2003; 125: 1670-1677
    CrossrefPubMedGoogle Scholar
  • 4 Shaheen N, Crosby M, Bozymski E, Sandler RS. Is there a publication bias in the reporting of cancer risk in Barrett’s esophagus?. Gastroenterology 2000; 119: 333-338
    CrossrefPubMedGoogle Scholar
  • 5 Desai TK, Krishnan K, Samala N, Singh J, Cluley J, Perla S, Howden CW. The incidence of oesophageal adenocarcinoma in non-dysplastic Barrett’s oesophagus: a meta-analysis. Gut 2012; 61: 970-976
    CrossrefPubMedGoogle Scholar
  • 6 Hvid-Jensen F, Pedersen L, Drewes AM, Sørensen HT, Funch-Jensen P. Incidence of adenocarcinoma among patients with Barrett’s esophagus. N Engl J Med 2011; 365: 1375-1383
    CrossrefPubMedGoogle Scholar
  • 7 Bhat S, Coleman HG, Yousef F, Johnston BT, McManus DT, Gavin AT, Murray LJ. Risk ofmalignant progression in Barrett’s esophagus patients: results from a large population-based study. J Natl Cancer Inst 2011; 103: 1049-1057
    CrossrefPubMedGoogle Scholar
  • 8 Pohl H, Welch HG. The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst 2005; 97: 142-146
    CrossrefPubMedGoogle Scholar
  • 9 Banki F, Demeester SR, Mason RJ, Campos G, Hagen JA, Peters JH, Bremner CG, Demeester TR. Barrett’s esophagus in females: a comparative analysis of risk factors in females and males. Am J Gastroenterol 2005; 100: 560-567
    CrossrefPubMedGoogle Scholar
  • 10 Labenz J, Jaspersen D, Kulig M, Leodolter A, Lind T, Meyer-Sabellek W, Stolte M, Vieth M, Willich S, Malfertheiner P. Risk factors for erosive esophagitis: a multivariate analysis based on the ProGERD study initiative. Am J Gastroenterol 2004; 99: 1652-1656
    CrossrefPubMedGoogle Scholar
  • 11 GOSPE . Barrett’s esophagus: epidemiological and clinical results of a multicentric survey. Gruppo Operativo per lo Studio delle Precancerosi dell’Esofago (GOSPE). Int J Cancer 1991; 48: 364-368
    CrossrefPubMedGoogle Scholar
  • 12 Cameron AJ, Lomboy CT. Barrett’s esophagus: age, prevalence, and extent of columnar epithelium. Gastroenterology 1992; 103: 1241-1245
    CrossrefPubMedGoogle Scholar
  • 13 Conio M, Cameron AJ, Romero Y, Branch CD, Schleck CD, Burgart LJ, Zinsmeister AR, Melton 3rd LJ, Locke 3rd GR. Secular trends in the epidemiology and outcome of Barrett’s oesophagus in Olmsted County, Minnesota. Gut 2001; 48: 304-309
    CrossrefPubMedGoogle Scholar
  • 14 van Blankenstein M, Looman CW, Johnston BJ. Age and sex distribution of the prevalence of Barrett’s esophagus found in a primary referral endoscopy center. Am J Gastroenterol 2005; 100: 568-576
    CrossrefPubMedGoogle Scholar
  • 15 Derakhshan MH, Liptrot S, Paul J, Brown IL, Morrison D, McColl KE. Oesophageal and gastric intestinal-type adenocarcinomas show the same male predominance due to a 17 year delayed development in females. Gut 2009; 58: 16-23
    CrossrefPubMedGoogle Scholar
  • 16 Solaymani-Dodaran M, Logan RF, West J, Card T, Coupland C. Risk of oesophageal cancer in Barrett’s oesophagus and gastro-oesophageal reflux. Gut 2004; 53: 1070-1074
    CrossrefPubMedGoogle Scholar
  • 17 Palli D, Cipriani F, Decarli A, Galli M, Saieva C, Fraumeni Jr JF, Blot WJ, Buiatti E. Reproductive history and gastric cancer among post-menopausal women. Int J Cancer 1994; 56: 812-815
    CrossrefPubMedGoogle Scholar
  • 18 Frise S, Kreiger N, Gallinger S, Tomlinson G, Cotterchio M. Menstrual and reproductive risk factors and risk for gastric adenocarcinoma in women: findings from the Canadian national enhanced cancer surveillance system. Ann Epidemiol 2006; 16: 908-916
    CrossrefPubMedGoogle Scholar
  • 19 Lindblad M, Garcia Rodriguez LA, Chandanos E. Hormone replacement therapy and risks of oesophageal and gastric adenocarcinomas. Br J Cancer 2006; 94: 136-141
    CrossrefPubMedGoogle Scholar
  • 20 Naugler WE, Sakurai T, Kim S, Maeda S, Kim K, Elsharkawy AM, Karin M. Gender disparity in liver cancer due to sex differences inMyD88-dependent IL-6 production. Science 2007; 317: 121-124
    CrossrefPubMedGoogle Scholar
  • 21 Harnish DC. Estrogen receptor ligands in the control of pathogenic inflammation. Curr Opin Investig Drugs 2006; 7: 997-1001
    PubMedGoogle Scholar
  • 22 Huang X. Iron overload and its association with cancer risk in humans: evidence for iron as a carcinogenic metal. Mutat Res 2003; 533: 153-171
    CrossrefPubMedGoogle Scholar
  • 23 Mainous 3rd AG, Wells BJ, Koopman RJ, Everett CJ, Gill JM. Iron, lipids, and risk of cancer in the Framingham Offspring cohort. Am J Epidemiol 2005; 161: 1115-1122
    CrossrefPubMedGoogle Scholar
  • 24 Lee DH, Anderson KE, Folsom AR, Folsom AR, Jacobs Jr. DR. Heme iron, zinc and upper digestive tract cancer: the Iowa Women’s Health Study. Int J Cancer 2005; 117: 643-647
    CrossrefPubMedGoogle Scholar
  • 25 Mainous 3rd AG, Gill JM, Everett CJ. Transferrin saturation, dietary iron intake, and risk of cancer. Ann Fam Med 2005; 3: 131-137
    CrossrefPubMedGoogle Scholar